Acquisition of bolus with unique delivery technology to enhance ruminant product range
Bimeda announced today that it has acquired UK based Telsol Limited. Telsol manufacture and market a range of large animal boluses that deliver superior benefits to livestock in the areas of weight gain and fertility, in particular.
The boluses are different to other boluses on the market in that they are based on a unique delivery technology, developed by Dr Stewart Telfer in conjunction with the University of Leeds and Pilkington Glass. The delivery technology chemically combines the trace elements to be released with soluble glass, thus ensuring a controlled release of the trace elements over the entire bolus lifetime. The company is best known for its Cosecure bolus, which is uniquely effective where Thiomolybdate toxicity or true copper deficiency is evident. Thiomolybdate toxicity, often undiagnosed or misdiagnosed, is a significant cause of poor fertility in cattle.
One of the very few trace element boluses globally to possess a Marketing Authorisation, Cosecure is manufactured, along with the other boluses in the range under GMP conditions at the company’s facility in Denbigh, Wales. The range is distributed in over fifteen markets worldwide.
Commenting on the acquisition, Ian Simington CEO Bimeda Europe said, “Telsol’s boluses with their proven differentiated benefits are a good fit for the Bimeda ruminant product range and enhance our offer to customers. We look forward to working with the team at Telsol to further develop the business”.
Bimeda Animal Health, with its headquarters in Dublin Ireland, develops and manufactures a wide range of veterinary and animal health products which are sold across all five continents in more than seventy five countries. The company's main focus is the development of high quality preventatives and treatments primarily focussed on livestock, poultry and horses.